Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
2013 · Clinical Cancer Research · 456 citations
https://doi.org/10.1158/1078-0432.ccr-12-3791
N
Nizar M. Tannir
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.0K
Papers
31.3K
Citations
83
h-index
330
i10-index
Nizar M. Tannir is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Renal cell carcinoma treatment & Renal and related cancers & Cancer Genomics and Diagnostics. The author has an h-index of 83, co-authored 887 publications.
ORCID: 0000-0001-5559-8060Papers by this author
worksNivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
2020 · Cancer · 331 citations
https://doi.org/10.1002/cncr.33033
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience
2019 · Journal for ImmunoTherapy of Cancer · 289 citations
https://doi.org/10.1186/s40425-018-0478-8
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
2018 · Cancer Cell · 239 citations
https://doi.org/10.1016/j.ccell.2018.10.007
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
2020 · Nature Communications · 169 citations
https://doi.org/10.1038/s41467-020-15959-6
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
2024 · Annals of Oncology · 157 citations
https://doi.org/10.1016/j.annonc.2024.07.727
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat